B²N²: Resource efficient Bayesian neural network accelerator using Bernoulli sampler on FPGA

A resource efficient hardware accelerator for Bayesian neural network (BNN) named B²N², Bernoulli random number based Bayesian neural network accelerator, is proposed. As neural networks expand their application into risk sensitive domains where mispredictions may cause serious social and economic losses, evaluating the NN’s confidence on its prediction has emerged as a critical concern. Among many uncertainty evaluation methods, BNN provides a theoretically grounded way to evaluate the uncertainty of NN’s output by treating network parameters as random variables. By exploiting the central limit theorem, we propose to replace costly Gaussian random number generators (RNG) with Bernoulli RNG which can be efficiently implemented on hardware since the possible outcome from Bernoulli distribution is binary. We demonstrate that B²N² implemented on Xilinx ZCU104 FPGA board consumes only 465 DSPs and 81661 LUTs which corresponds to 50.9% and 14.3% reductions compared to Gaussian-BNN (Hirayama et al., 2020) implemented on the same FPGA board for fair comparison. We further compare B²N² with VIBNN (Cai et al., 2018), which shows that B²N² successfully reduced DSPs and LUTs usages by 50.9% and 57.9%, respectively. Owing to the reduced hardware resources, B²N² improved energy efficiency by 7.50% and 57.5% compared to Gaussian-BNN (Hirayama et al., 2020) and VIBNN (Cai et al., 2018), respectively

Tumor Shrinkage in Response to Vitamin K2 in Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report

Introduction: Advanced or metastatic hepatocellular carcinoma (HCC) can be lethal because of the limited therapeutic approach such as sorafenib. Recently, Vitamin K2 (VK2) has been increasingly recognized to have anti-cancer effects for HCC in vitro and vivo. However, the direct anti-cancer effect of VK2 to HCC has not been established yet in human.Presentation of Case: We presented here a 88-year-HCC patient displayed a tumor shrinkage in response to VK2 in multiple lung metastases, indicating the possibility of VK2 as an anti-cancer agent in human. Menatetrenone, a VK2 analogue, was introduced for multiple lung metastases as a palliative treatment, and thereafter multiple lung metastases, except one lung lesion, displayed tumor shrinkage and disappeared within five months after VK2 intake. The residual one lesion continued to grow up during the intake of VK2, suggesting that the residual tumor was insensitive to VK2 represented by tumor heterogeneity. Consequently, after a radiation therapy for the residual lesion, the elevated tumor markers of all were finally decreased into normal levels, and he is still alive for 18 months after VK2 intake without elevated tumor marker levels and toxic adverse effects.Conclusion:VK2 may be a therapeutic option for advanced and metastatic HCCs without any toxic adverse

Long-Term Outcome of Proton Therapy and Carbon-Ion Therapy for Large (T2a–T2bN0M0) Non–Small-Cell Lung Cancer

IntroductionAlthough many reports have shown the safety and efficacy of stereotactic body radiotherapy (SBRT) for T1N0M0 non–small-cell lung cancer (NSCLC), it is rather difficult to treat T2N0M0 NSCLC, especially T2b (>5 cm) tumor, with SBRT. Our hypothesis was that particle therapy might be superior to SBRT in T2 patients. We evaluated the clinical outcome of particle therapy for T2a/bN0M0 NSCLC staged according to the 7th edition of the International Union Against Cancer (UICC) tumor, node, metastasis classification.MethodsFrom April 2003 to December 2009, 70 histologically confirmed patients were treated with proton (n = 43) or carbon-ion (n = 27) therapy according to institutional protocols. Forty-seven patients had a T2a tumor and 23 had a T2b tumor. The total dose and fraction (fr) number were 60 (Gray equivalent) GyE/10 fr in 20 patients, 52.8 GyE/4 fr in 16, 66 GyE/10 fr in 16, 80 GyE/20 fr in 14, and other in four patients, respectively. Toxicities were scored according to the Common Terminology Criteria for Adverse Events, Version 4.0.ResultsThe median follow-up period for living patients was 51 months (range, 24–103). For all 70 patients, the 4-year overall survival, local control, and progression-free survival rates were 58% (T2a, 53%; T2b, 67%), 75% (T2a, 70%; T2b, 84%), and 46% (T2a, 43%; T2b, 52%), respectively, with no significant differences between the two groups. The 4-year regional recurrence rate was 17%. Grade 3 pulmonary toxicity was observed in only two patients.ConclusionParticle therapy is well tolerated and effective for T2a/bN0M0 NSCLC. To further improve treatment outcome, adjuvant chemotherapy seems a reasonable option, whenever possible

Notes on Giant Gravitons on PP-waves

We investigate the giant gravitons in the maximally supersymmetric IIB pp-wave from several viewpoints: (i) the dynamics of D3-branes, (ii) the world-sheet description and (iii) the correlation functions in the dual N=4 Yang-Mills theory. In particular, we derive the BPS equation of a D3-brane with magnetic flux, which is equivalent to multiple D-strings, and discuss the behavior of solutions in the presence of RR-flux. We find solutions which represent the excitations of the giant gravitons in that system.Comment: 25 pages, Latex, typos corrected, (minor) factors in eq.(2.11),(2.12),(2.16),(2.17) corrected, a footnote added, to appear in JHE

Quantum hydrodynamics

Quantum hydrodynamics in superfluid helium and atomic Bose-Einstein condensates (BECs) has been recently one of the most important topics in low temperature physics. In these systems, a macroscopic wave function appears because of Bose-Einstein condensation, which creates quantized vortices. Turbulence consisting of quantized vortices is called quantum turbulence (QT). The study of quantized vortices and QT has increased in intensity for two reasons. The first is that recent studies of QT are considerably advanced over older studies, which were chiefly limited to thermal counterflow in 4He, which has no analogue with classical traditional turbulence, whereas new studies on QT are focused on a comparison between QT and classical turbulence. The second reason is the realization of atomic BECs in 1995, for which modern optical techniques enable the direct control and visualization of the condensate and can even change the interaction; such direct control is impossible in other quantum condensates like superfluid helium and superconductors. Our group has made many important theoretical and numerical contributions to the field of quantum hydrodynamics of both superfluid helium and atomic BECs. In this article, we review some of the important topics in detail. The topics of quantum hydrodynamics are diverse, so we have not attempted to cover all these topics in this article. We also ensure that the scope of this article does not overlap with our recent review article (arXiv:1004.5458), "Quantized vortices in superfluid helium and atomic Bose--Einstein condensates", and other review articles.Comment: 102 pages, 29 figures, 1 tabl

The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016)

Background and purposeThe Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016), a Japanese-specific set of clinical practice guidelines for sepsis and septic shock created jointly by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first released in February 2017 and published in the Journal of JSICM, [2017; Volume 24 (supplement 2)] https://doi.org/10.3918/jsicm.24S0001 and Journal of Japanese Association for Acute Medicine [2017; Volume 28, (supplement 1)] http://onlinelibrary.wiley.com/doi/10.1002/jja2.2017.28.issue-S1/issuetoc.This abridged English edition of the J-SSCG 2016 was produced with permission from the Japanese Association of Acute Medicine and the Japanese Society for Intensive Care Medicine.MethodsMembers of the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine were selected and organized into 19 committee members and 52 working group members. The guidelines were prepared in accordance with the Medical Information Network Distribution Service (Minds) creation procedures. The Academic Guidelines Promotion Team was organized to oversee and provide academic support to the respective activities allocated to each Guideline Creation Team. To improve quality assurance and workflow transparency, a mutual peer review system was established, and discussions within each team were open to the public. Public comments were collected once after the initial formulation of a clinical question (CQ) and twice during the review of the final draft. Recommendations were determined to have been adopted after obtaining support from a two-thirds (> 66.6%) majority vote of each of the 19 committee members.ResultsA total of 87 CQs were selected among 19 clinical areas, including pediatric topics and several other important areas not covered in the first edition of the Japanese guidelines (J-SSCG 2012). The approval rate obtained through committee voting, in addition to ratings of the strengths of the recommendation, and its supporting evidence were also added to each recommendation statement. We conducted meta-analyses for 29 CQs. Thirty-seven CQs contained recommendations in the form of an expert consensus due to insufficient evidence. No recommendations were provided for five CQs.ConclusionsBased on the evidence gathered, we were able to formulate Japanese-specific clinical practice guidelines that are tailored to the Japanese context in a highly transparent manner. These guidelines can easily be used not only by specialists, but also by non-specialists, general clinicians, nurses, pharmacists, clinical engineers, and other healthcare professionals